This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

4 Reasons Why TrueCar's Stock Is Poised to Re-accelerate

The stock has been punished too severely. Here's why it should bounce back.

Papa Murphy's Investors Should Flee Kitchen Before They Get Burned

Papa Murphy's shares have had a good run so far this year. Here's why it won't last.

3 Oncology Biotechs to Watch
3 Oncology Biotechs to Watch

01/27/14 - 09:21 AM EST

Handicapping the potential of Galena Biopharma, CytRx and Northwest Biotherapeutics requires a solid understanding of what has been driving share prices.

Best Trade for Renewable Energy Is Short

Though Renewable Energy's Tuesday's acquisition of Syntroleum is puzzling, it is easy to see why REGI, PLUG and other new energy stocks could be set for sharp drops.

Napco, Lionbridge: 2 Small-Caps Making Big Moves

Some of the best investment calls in 2013 have been among small-mid cap tech and healthcare stocks trading for $5-$10 with medium-term catalysts.

A Closer Look at Quest Diagnostics, Lab Corp and Hologic

Obamacare may not these diagnostic stocks higher, but it is likely to give them meaningful boosts in revenue.

Watch for a Big Short Squeeze in Cleantech Solutions

With short interest rising and the potential for a strong earnings announcement, CleanTech could soon re-test its high for the year of around $11.

Watch CodeSmart Reap Revenue Windfall
Watch CodeSmart Reap Revenue Windfall

10/18/13 - 05:00 AM EDT

Expect a sharp move upward for CodeSmart in a few weeks when it reports its first major revenue.

Biozone: A Little Biotech Setting Up for Big Gains

Biozone is very likely to look like a no-brainer by year-end.

Beware the Chinese Rumor Mill
Beware the Chinese Rumor Mill

06/07/13 - 11:21 AM EDT

Watch out for the companies that reverse-split to avoid delisting and then are the subject of explosive rumors. They are rife for manipulation.

Page 1 of 9
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs